These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19401694)

  • 1. Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
    Xue H; Field CJ; Sawyer MB; Dieleman LA; Baracos VE
    Br J Cancer; 2009 May; 100(10):1581-8. PubMed ID: 19401694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
    Hu ZP; Yang XX; Chan SY; Xu AL; Duan W; Zhu YZ; Sheu FS; Boelsterli UA; Chan E; Zhang Q; Wang JC; Ee PL; Koh HL; Huang M; Zhou SF
    Toxicol Appl Pharmacol; 2006 Oct; 216(2):225-37. PubMed ID: 17015070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour.
    Xue H; Le Roy S; Sawyer MB; Field CJ; Dieleman LA; Baracos VE
    Br J Nutr; 2009 Aug; 102(3):434-42. PubMed ID: 19250573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
    Cao S; Black JD; Troutt AB; Rustum YM
    Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
    Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC
    BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.
    Lin XB; Dieleman LA; Ketabi A; Bibova I; Sawyer MB; Xue H; Field CJ; Baracos VE; Gänzle MG
    PLoS One; 2012; 7(7):e39764. PubMed ID: 22844397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
    Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
    Swami U; Goel S; Mani S
    Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
    Wang J; Jia LQ; Tan HY; Pan L; Yu LL; Deng B
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1236-43. PubMed ID: 26677677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
    Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
    Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Guffroy M; Hodge T
    J Natl Cancer Inst; 1996 Sep; 88(17):1240-1. PubMed ID: 8780636
    [No Abstract]   [Full Text] [Related]  

  • 18. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
    Fittkau M; Voigt W; Holzhausen HJ; Schmoll HJ
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):388-94. PubMed ID: 15160289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
    Gibson RJ; Bowen JM; Keefe DM
    Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.